給藥技術領域的有效交易

給藥技術領域的有效交易 是由出版商PharmaVentures Ltd在2009年01月所出版的。 這份英文市場調查報告書包含142 Pages 價格從美金5993起跳。

簡介

目錄

Abstract

“Looming patent expiry a major force in driving valuation”

Drugs with annual sales totalling over US$86 B in 2007 are due to go off patent by 2012. Therefore, the application of novel drug delivery technologies to such existing therapeutics is an attractive means of prolonging the commerical viability of marketed drugs.

Technologies are more difficult to value than products in clinical development because the technical risks or success rates are less well documented, and costs and timescales are less predictable.

It is very important to benchmark when valuing technologies and to have a thorough understanding of the risks and rewards.

This new PharmaDealsR Report, covers the range of strategies and offerings available to the deal maker, and is vital for understanding growth and survival in volatile markets.

Table of Contents

1. Introduction

2. Market Overview

• 2.1 Types of Drug Delivery
• 2.2 Development of the Drug Delivery Market
• 2.3 The Current and Evolving Market
• 2.4 Future Market Challenges
• 2.5 Drug Delivery Companies
  • 2.5.1 Principal Players in Drug Delivery
  • 2.5.2 The Changing Landscape: M&A Activity
  • 2.5.3 The True Scope of the Drug Delivery Sector

3. Key Drivers in Drug Delivery

• 3.1 Improving the Therapeutic Index
• 3.2 Patient Compliance
• 3.3 Patent Prolongation
• 3.4 Life Cycle Management

4. Commercialisation Strategies

• 4.1 Introduction
• 4.2 Returns to Innovation
• 4.3 Drug Delivery Product Offerings
• 4.4 Exploitation Strategies
• 4.5 Business Models
• 4.6 Product, Strategy and Business Models for Drug Delivery Technology
• 4.7 Applicability to Segments of the Pharmaceutical Product Life Cycle
• 4.8 Assessment of Attractiveness of Each Option
  • 4.8.1 Divestment to a Service-Based Company
  • 4.8.2 Licensing to Pharmaceutical Companies
  • 4.8.3 Sales of Devices
  • 4.8.4 Service Offering
  • 4.8.5 Development of Drugs in Collaboration with other Companies
  • 4.8.6 In-House Drug Development
• 4.9 Compatibility of Product Offerings
• 4.10 Conclusion

5. Alliances in Drug Delivery

• 5.1 Drug Delivery Deals Database
• 5.2 Drug Delivery Deal Activity
• 5.3 Financial Analysis of Drug Delivery Deals

6. Major Pharmaceutical Company Drug Delivery Deal Activity

• 6.1 Johnson & Johnson
• 6.2 Pfi zer
• 6.3 GlaxoSmithKline (GSK)
• 6.4 Novartis
• 6.5 Sanofi -aventis
• 6.6 Roche
• 6.7 AstraZeneca
• 6.8 Merck & Co
• 6.9 Abbott Laboratories
• 6.10 Wyeth

7. Valuation Methods

• 7.1 Integrated Benchmarking and ENPV Calculation
• 7.2 Other Methods
• 7.3 Benchmarking
  • 7.3.1 Feasibility Search
  • 7.3.2 Information Gathering and Analysis
  • 7.3.3 Approximate Valuation
  • 7.3.4 Refi nement of Valuation
• 7.4 Expected Net Present Value
• 7.5 Agreement Structure
  • 7.5.1 Value Sharing
  • 7.5.2 Risk Sharing
• 7.6 Valuation of Drug Delivery Systems
  • 7.6.1 Enabling Technology
  • 7.6.2 Enhancing Technology

8. Drug Delivery Alliance Development Process

• 8.1 Needs Identifi cation
  • 8.1.1 Driving Factors
    • 8.1.1.1 Market Drivers
    • 8.1.1.2 Technology Drivers
  • 8.1.2 Tools Needs Identifi cation
    • 8.1.2.1 Portfolio Analysis
    • 8.1.2.2 Value Chain Analysis
• 8.2 Identifying Opportunities and Partners
• 8.3 Development of Commercial Relationships

9. Drug Delivery Agreements

• Table of drug delivery agreements linked to the PharmaDeals® v2 Agreements Database

Tables

• 1. Typical maximum doses per administration
• 2. Marketed recombinant biopharmaceuticals among the top 200 selling prescription drugs
• 3. Publicly quoted specialty pharmaceutical companies that focus on drug delivery
• 4. Elan' s partnering activity
• 5. Major patent expirations, 2008 - 2012
• 6. Strategies for the exploitation of innovation
• 7. Business models
• 8. Generic strategies for commercialisation
• 9. Product offerings and target segments
• 10. Compatibility of product offerings
• 11. Number of drug delivery deals by therapeutic area, 1997 - October 2008
• 12. Number of drug delivery deals by product type, 1997 - October 2008
• 13. Average total deal values for drug delivery deals, 1997 - October 2008
• 14. Average upfront payments for drug delivery deals, 1997 - October 2008
• 15. Average milestone payments for drug delivery deals, 1997 - October 2008
• 16. Average equity investment payments for drug delivery deals, 1997 - October 2008
• 17. Top ten pharmaceutical companies by 2007 worldwide healthcare revenue
• 18. Johnson & Johnson drug delivery deals
• 19. Alza drug delivery deals (part of Johnson & Johnson)
• 20. Pfizer drug delivery deals
• 21. Pharmacia drug delivery deals
• 22. GlaxoSmithKline drug delivery deals
• 23. Novartis drug delivery deals
• 24. Sanofi-aventis drug delivery deals
• 25. Roche drug delivery deals
• 26. AstraZeneca drug delivery deals
• 27. Abbott drug delivery deals
• 28. Merck & Co. drug delivery deals
• 29. Wyeth drug delivery deals
• 30. Benchmarking methodology overview
• 31. Sources of information
• 32. Cumulative probabilities
• 33. Example ENPV calculation
• 34. Pharmaceutical industry event calendars
• 35. Key factors leading to successful alliances between companies
• 36. Drug delivery agreements linked to PharmaDeals

Figures

• 1. Pharmaceutical company R&D drug delivery projects by route of delivery
• 2. Drug delivery mergers and acquisitions, 1997 - 2008
• 3. Effect of controlled release formulations
• 4. Doses of chemotherapeutic agent required to achieve maximum effect
• 5. Estimated value in 2008 worldwide sales of the top 200 prescription drugs by year of US patent expiry
• 6. Life cycle management
• 7. All deal activity, 1997 - 2008
• 8. Drug delivery deal activity, 1997 - 2008
• 9. All deals according to deal type, 1997 - 2008
• 10. Drug delivery deals according to deal type, 1997 - 2008
• 11. Number of drug delivery deals by therapeutic area, 1997 - 2008
• 12. Number of drug delivery deals by product type, 1997 - 2008
• 13. Percentage of all deals with some financial information, 1997 - 2008
• 14. Percentage of drug delivery deals with some financial information, 1997 - 2008
• 15. Integrated valuation methods
• 16. Ideal benchmarking deal cluster
• 17. Example pharmaceutical deal force field
• 18. Attrition by therapeutic area
• 19. Success rates for life cycle management projects
• 20. Pharmaceutical product decision tree
• 21. Enhanced revenues due to drug delivery system
• 22. Enhancement of patent life
• 23. Drug delivery alliance development process

相關商品

DDS相關市場調查報告書

胰島素給藥設備:全球開發平台分析機會評估及與到2017年為止的市場預測
Insulin Delivery Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
價格 : US $ 3995
出版日期 : 2012年01月

經皮藥物給藥：技術・市場・企業
Transdermal Drug Delivery - Technologies, Markets, and Companies
價格 : US $ 3000
出版日期 : 2012年01月

癌症相關之藥物傳輸：技術、市場、企業
Drug Delivery in Cancer - technologies, markets and companies
價格 : US $ 4000
出版日期 : 2012年01月

PharmaVentures Ltd發行的製藥相關市場調查報告書

重要交易動向：癌（2011年）

Essential Deal Trends: Oncology 2011

價格 : US $ 2395

出版日期 : 2011年10月

疫苗領域的交易分析

Analysis of Deal Making in Vaccines

價格 : US $ 3344

出版日期 : 2010年11月

神經退化疾病的交易分析

Analysis of Deals in Neurodegenerative Diseases

價格 : US $ 3344

出版日期 : 2010年07月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!